You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 18, 2025

Drugs in MeSH Category Adrenergic alpha-2 Receptor Antagonists


✉ Email this page to a colleague

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sunovion Pharms Inc LATUDA lurasidone hydrochloride TABLET;ORAL 200603-002 Oct 28, 2010 AB RX Yes No 8,883,794*PED ⤷  Try for Free Y ⤷  Try for Free
Sunovion Pharms Inc LATUDA lurasidone hydrochloride TABLET;ORAL 200603-002 Oct 28, 2010 AB RX Yes No 9,907,794*PED ⤷  Try for Free Y ⤷  Try for Free
Jubilant Generics LURASIDONE HYDROCHLORIDE lurasidone hydrochloride TABLET;ORAL 210388-005 Dec 6, 2024 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Sunovion Pharms Inc LATUDA lurasidone hydrochloride TABLET;ORAL 200603-003 Dec 7, 2011 AB RX Yes No 8,883,794*PED ⤷  Try for Free Y ⤷  Try for Free
Jubilant Generics LURASIDONE HYDROCHLORIDE lurasidone hydrochloride TABLET;ORAL 210388-002 Dec 6, 2024 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Watson Labs Teva LURASIDONE HYDROCHLORIDE lurasidone hydrochloride TABLET;ORAL 208016-001 Feb 2, 2021 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Heritage Pharma Avet LURASIDONE HYDROCHLORIDE lurasidone hydrochloride TABLET;ORAL 208058-001 Sep 4, 2019 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Adrenergic alpha-2 Receptor Antagonists Market Analysis and Financial Projection

The market dynamics and patent landscape for adrenergic alpha-2 receptor antagonists reveal a niche but evolving sector within the pharmaceutical industry, driven by therapeutic innovation and expanding applications. Here's a comprehensive analysis:


Market Dynamics

Growth Projections and Drivers

  • The alpha-2 adrenergic antagonist market is indirectly influenced by broader trends in adrenergic drug development. While direct market figures for antagonists are less prominent, related segments like the yohimbine market (a well-known alpha-2 antagonist) are anticipated to grow due to increasing use in dietary supplements and off-label applications for depression and anxiety[17].
  • Key therapeutic areas driving demand include:
    • Mental health: Alpha-2 antagonists like idazoxan XR are under investigation for schizophrenia[18], with companies like Terran Biosciences advancing clinical trials.
    • Veterinary medicine: Antagonists such as atipamezole are critical for reversing sedation caused by alpha-2 agonists like dexmedetomidine[14].
    • Ophthalmology: Research highlights their neuroprotective potential in glaucoma by modulating NMDA receptor function[3].

Regional Insights

  • North America dominates due to robust R&D activity and high prevalence of mental health disorders[5][17]. For example, ~8.7 million U.S. adults have ADHD, a condition historically treated with alpha-2 antagonists like guanfacine[5].
  • Asia-Pacific shows growth potential, driven by rising hypertension rates (15–35% in urban populations) and increasing healthcare investments[5][12].

Challenges

  • Side effects: Sedation, hypotension, and dizziness limit broader clinical adoption[5][17].
  • Regulatory hurdles: Restrictions on yohimbine in some regions due to safety concerns[17].
  • Competition: Alternative therapies, including non-pharmacological interventions, challenge market penetration[5].

Patent Landscape

Recent Innovations

  • ADRA2A Antagonists: Structure-activity studies on yohimbine derivatives (e.g., compound 4n) have yielded selective antagonists with 556-fold selectivity for ADRA2A over ADRA2B receptors[4].
  • Analgesic Formulations: Patent US20230372309A1 covers compositions using alpha-2 antagonists for pain management, emphasizing reduced opioid reliance[9][13].
  • Neuroprotection: Patents like US10668094B2 target Na,K-ATPase inhibitors to lower intraocular pressure, leveraging alpha-2 receptor interactions[2].

Strategic Acquisitions

  • Companies like Terran Biosciences are acquiring patent portfolios to advance CNS drugs. For example, their exclusive rights to idazoxan XR for schizophrenia highlight a focus on late-stage clinical assets[18].
  • Legal disputes, such as Terran’s lawsuit against COMPASS Pathways over psilocybin-related IP, underscore the competitive nature of neuropharmacology patents[18].

Key Players and Trends

Company/Entity Focus Area Notable Activity
Pfizer/Merck Broad adrenergic drug pipeline Investing in agonist-antagonist combos[5]
Terran Biosciences CNS disorders Developing idazoxan XR for schizophrenia[18]
Boehringer Ingelheim Neuroprotection Exploring NMDA receptor modulation[3]

Emerging Trends

  • Precision Medicine: AI-driven drug discovery is accelerating the development of subtype-selective antagonists (e.g., ADRA2A vs. ADRA2B)[4][8].
  • Combination Therapies: Pairing alpha-2 antagonists with psychedelics (e.g., psilocybin) to enhance therapeutic outcomes[18].

Future Outlook

  • The market is poised for 5.5–8.7% CAGR through 2033, fueled by unmet needs in mental health and chronic disease[5][12].
  • Patent Expirations: Expiry of key patents (e.g., US10668094B2 in 2024) may open opportunities for generics[2].
  • Innovation Hotspots: Focus on reducing off-target effects (e.g., alpha-2C receptor selectivity) and improving bioavailability[4][9].

“Alpha-2 antagonists are transitioning from veterinary reversal agents to groundbreaking CNS therapeutics, with neuroprotection and neuromodulation as key frontiers.” [3][9]


This sector’s growth hinges on overcoming tolerability issues and leveraging technological advancements in drug design. Strategic patent filings and partnerships will remain critical for market leadership.

References

  1. https://sites.google.com/view/real-timebusinessresearchinsig/reports/alpha2-adrenergic-agonist-market
  2. https://patents.google.com/patent/US10668094B2/en
  3. https://pubmed.ncbi.nlm.nih.gov/18566471/
  4. https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c00323
  5. https://www.researchnester.com/reports/alpha-2-receptor-agonists-market/3265
  6. https://www.drugpatentwatch.com/p/patent/6673337
  7. https://pubmed.ncbi.nlm.nih.gov/17266605/
  8. https://github.com/jugutstam/Market-Research-Report-List-1/blob/main/a2-adrenergic-agonist-market.md
  9. https://patents.google.com/patent/US20230372309A1/en
  10. https://pubmed.ncbi.nlm.nih.gov/18579700/
  11. https://www.aoa.org/assets/documents/EBO/CRG%20-%20GLAUCOMA%204/934-003ARTHUR2011.pdf
  12. https://www.verifiedmarketreports.com/product/alpha-2-adrenergic-agonist-market/
  13. https://patents.google.com/patent/US20230372309A1/fr
  14. https://en.wikipedia.org/wiki/Alpha-2_blocker
  15. https://karger.com/nen/article/39/3/275/222353/Role-of-Alpha1-and-Alpha2-Adrenergic-Receptors-in
  16. https://pubmed.ncbi.nlm.nih.gov/9399373/
  17. https://www.alliedmarketresearch.com/yohimbine-market-A13573
  18. https://psychedelicalpha.com/news/analysis-patent-applications-provide-hints-at-terran-biosciences-strategy

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.